<DOC>
	<DOC>NCT00744991</DOC>
	<brief_summary>The purpose of the study is to determine the efficacy and safety of enzastaurin in patients with CTCL who failed prior therapies.</brief_summary>
	<brief_title>A Study for Patients With Relapsed Cutaneous T-Cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, T-Cell</mesh_term>
	<mesh_term>Lymphoma, T-Cell, Cutaneous</mesh_term>
	<criteria>Histologically confirmed mycosis fungoides or Sezary Syndrome Stage IB to IVB disease at screening Recurrent or refractory disease after at least 1 prior systemic therapy Have adequate organ function defined as: At least 30 days must have passed since other treatment for CTCL. Receiving concurrent treatment for CTCL Unable to swallow tablets Receiving high potency oral or topical steroids. Low potency oral steroid may be permitted in patients who have been on a stable dose for at least 4 weeks prior to screening. Oral or topical antihistamine is allowed. Unable to discontinue use of carbamazepine, phenobarbital, or phenytoin Have a serious concomitant systemic disorder or HIV Have a serious cardiac condition such as myocardial infarction within past 6 months, angina, or heart disease as defined by the New York Heart Association (NYHA) Class III or IV Have ECG abnormalities, Are pregnant or breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
</DOC>